Global Alendronic Acid Market Size, Share and Trends Analysis Report, By Type (70 mg Tablet and 10 mg Tablet), By Application (Paget’s Disease, Osteoporosis, Tumor-Associated Hypercalcemia, Osteogenesis Imperfecta, and Others), Forecast (2022-2028)

The global alendronic acid market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). An alendronic acid is a form of vitamin D which is used for the treatment of osteoporosis. The major factor expected to drive the market growth is the rising consumer awareness about alendronate sodium, the rising geriatric population, and increasing demand for minimally invasive surgeries. Furthermore, its use in absorbing calcium from food, and also prevents bone loss by increasing the amount of calcium that bones absorb into them instead of releasing out through kidneys or urine. Moreover, it supports in improving bone strength and prevents fractures along with treating osteoporosis caused due to corticosteroids, other drugs, or cancer treatment that causes bone loss. These are the causes which drive the growth of the market during the forecast period.

Based on the product type, 70 mg tablet belongs to the group of bisphosphonates and it’s used for treating osteoporosis, Paget’s disease, or tumor-associated hypercalcemia. Further, treatment with this medication may slow down bone loss in people who are undergoing anti-resorptive therapy. Whereas, a 10 mg tablet is used in the treatment and prevention of osteoporosis in postmenopausal women, to reduce the risk for vertebral fracture along with it is used for the treatment of Paget’s disease and other conditions such as osteogenesis imperfecta (brittle bone disease), hypercalcemia, and tumor-associated hypercalcemia.

Based on application segment, alendronic acid is used to treat hypercalcemia resulting from the production of parathyroid hormone-related protein (PTHrP) in patients with solid tumors, particularly estrogen receptor-positive breast cancers or lymphomas. Moreover, alendronic acid is used as a treatment option in the management of osteogenesis imperfecta as it supports decreasing pain by increasing bone strength and stability resulting from fibrous dysplasia. Some major players in the market include Merck & Co., Inc., and Teva Pharmaceutical Industries Ltd., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

 

• Competitive Landscape– Merck & Co., Inc., and Teva Pharmaceutical Industries Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Alendronic Acid Market Report by Segment

By Type

• 70 Mg Tablet
• 10 Mg Tablet

By Application

• Paget’s Disease
• Osteoporosis
• Tumor-Associated Hypercalcemia
• Osteogenesis Imperfecta
• Others

Global Alendronic Acid Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa